Purchase this article with an account.
A. Varshney, J. Carlson; Treatment of Metastatic Choroidal Breast Cancer With Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5953.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of bevacizumab in the treatment of metastatic choroidal breast cancer
A 53 year old female was diagnosed with choroidal metastasis from breast cancer in the left eye. She was started on intravenous and intravitreal bevacizumab therapy for ocular metastasis. The response of bevacizumab on ocular metastasis of breast cancer was investigated with the use of fluorescein angiography (FA), and optical coherence tomography (OCT).
Within 6 weeks of the start of intravenous and intravitreal bevacizumab therapy the patient’s best corrected visual acuity (BCVA) improved from 20/80 to 20/25. There was complete resolution of subretinal edema on optical coherence tomography with no choroidal mass evident on exam. At 10 months the patient had no subretinal fluid on OCT examination and her fluorescein angiogram showed no active leakage. There was no evidence of choroidal recurrence and her visual acuity remained 20/25.
Choroidal metastasis from breast cancer appears to be very sensitive to a combination therapy of intravenous and intravitreal bevacizumab.
This PDF is available to Subscribers Only